The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ALNY stock soars 62% in a year, driven by increasing Amvuttra and Givlaari sales. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.

Novartis’ efforts to strengthen its wide portfolio ... For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% ...

Novartis AG (NYSE:NVS – Get Free Report) was the target of some unusual options trading activity on Tuesday. Investors acquired 54,767 call options on the stock. This represents an increase of 2,389% ...

NOVARTIS AG (ADR) (NVS) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 87% based on the firm’s underlying fundamentals and the stock’s ...

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Concurrent Investment Advisors LLC increased its holdings in Novartis by 11.8% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 3,734 shares of the company’s stock worth $429,000 ...

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

Travere Therapeutics' Filspari boosts revenue with FDA approval, but heavy losses and competitive threats raise concerns for ...